| || |
|Prev||Chapter 3. TREATMENT (Conventional Medicine)||Next|
Pegasys (peginterferon alpha-2a), Roche’s pegylated interferon, achieved a sustained virological response in 39% of patients, which is twice that achieved with the current treatment, interferon alpha-2a. The findings were presented at the 35th annual meeting of the European Association for the Study of the Liver (EASL), in Rotterdam, Netherlands, May 1-3, 2000. Pegasys is now approved in the US, Canada, and other countries.
|3.1.2a Pegylated Intron A (Peg-Intron A)||Up||3.1.3 Interferon Combinations|